ブログ

Explore VHH intrabodies for intracellular targeting, protein interaction studies, and therapeutic research applications. Learn more with Biointron.

Learn how site-directed mutagenesis improves antibody affinity, binding specificity, and performance for therapeutic and diagnostic applications.

Explore VHH Fc fusion and enzyme strategies to improve antibody half-life, effector functions, and targeted delivery. Learn more with Biointron.

The 2026 ChAbS Annual Conference, “10 Years Together: Forging the Future of Antibody Therapeutics,” was held on May 9-10, 2026, in Cambridge, MA.

​Biointron’s 2026 Lunch & Learn was held at CIC Cambridge, MA on May 8, 2026. The session featured two guest speakers: Shashi Jatiani, PhD, Director of Strategic Partnerships at SeromYx Systems, and Lee Andrews, Associate Director of Bioanalytical Development at Visterra.

BIO Korea 2026 was held on Aprill 28-30, 2026, bringing together academic scholars and experts in the biopharma and healthcare industry to share the latest technology trends and engage in discussion.

VHH half extension mechanisms like Fc fusion, albumin binding, and PEGylation to improve pharmacokinetics and performance. Contact Biointron.

Learn how multivalent and bispecific VHH antibodies are engineered, their advantages, applications, and key challenges in therapeutic development.

April 2026 activity saw consolidation in the ADC space, continued expansion of next-generation antibody formats (including DACs and trispecifics), and strong financing for platform-driven oncology innovation. Strategic M&A and high-value partnerships highlighted sustained interest in complex biologics and targeted delivery technologies.

Read on for key trends talked about during the conference: Antibody Therapeutics Xchange - Boston 2026, held on April 28.

Explore VHH antibody humanization strategies, challenges, and validation methods to reduce immunogenicity while preserving stability and binding.

The BioPlus Global Forum 2026, held alongside AACR, highlighted emerging antibody targets, next-generation modalities, and shifting global development dynamics, with a strong focus on GI oncology, early-stage innovation, and the growing influence of China in clinical strategy.